MXCT News and Press, MaxCyte Inc. From 01/02/24

2024-01-02 05:27:10 ET More on MaxCyte MaxCyte May Benefit From Potential Gene Therapy Approval MaxCyte announces departure of founder and CEO Doug Doerfler Seeking Alpha’s Quant Rating on MaxCyte For further details see: MaxCyte gets new CEO and P...

ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproce...

2023-12-12 16:51:29 ET Gainers: Innovative International Acquis ( IOAC ) +24% . EF Hutton Acquisition Corporation  ( EFHT ) +5% . Denali Therapeutics  ( DNLI ) +4% . SLM Corporation ( SLM ) +4% . BioCryst Pharmaceuticals ( BC...

2023-12-11 16:43:31 ET More on MaxCyte MaxCyte May Benefit From Potential Gene Therapy Approval MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript Gene editing stocks mixed despite world’s first CRISPR drug approval Biggest stock movers today: Black...

2023-11-27 08:00:00 ET Summary MaxCyte is a pick-and-shovel play on cell editing technology, but may capture a royalty stream from successful products. Vertex's potential candidate approval in the U.S. could prove a decisive catalyst ultimately validating MaxCyte's approach and bu...

2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...

2023-11-16 15:54:01 ET More on CRISPR Therapeutics CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A B...

ROCKVILLE, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovati...

2023-11-08 23:06:07 ET MaxCyte, Inc. (MXCT) Q3 2023 Earnings Conference Call November 8, 2023 04:30 PM ET Company Participants Sean Menarguez - Head of IR Doug Doerfler - President & CEO Douglas Swirsky - CFO Conference Call Participants Dan Arias...

2023-11-08 16:42:10 ET MaxCyte press release ( NASDAQ: MXCT ): Q3 GAAP EPS of -$0.11 misses by $0.01 . Revenue of $8M (-24.5% Y/Y) misses by $0.11M . Continue to expect to end the year with approximately $200 million in cash, cash equivalents and investments. ...